Study Summary
This trial is testing a new cancer treatment involving two drugs given after TheraSphere, to see if it is more effective at treating HCC than TheraSphere alone.
- Liver Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 53 Secondary · Reporting Duration: Treatment (Day 1) up to participant's death, opposition to data collection, lost to follow-up, or study termination (18 months after the last patient is randomized).
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
TheraSphere alone
1 of 2
TheraSphere followed by Durvalumab and Tremelimumab
1 of 2
Active Control
Experimental Treatment
150 Total Participants · 2 Treatment Groups
Primary Treatment: Tremelimumab immunotherapy · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there currently vacant spots available to participants in this research study?
"According to clinicaltrials.gov, this experiment is actively seeking patient enrollment and has been since December 1st 2022. The details of the research were last revised on November 18th 2022." - Anonymous Online Contributor
What potential adverse effects should be expected from Tremelimumab therapy?
"Our team has evaluated Tremelimumab [immunotherapy](https://www.withpower.com/clinical-trials/immunotherapy) and given it a rating of 2 due to clinical data which implies safety, but not yet efficacy." - Anonymous Online Contributor
Is this an innovative research project?
"Tremelimumab immunotherapy has seen an unprecedented level of clinical trial involvement since its first study in 2007. Hosted across 58 countries and 1327 different cities, 340 active trials have been conducted by AstraZeneca alone with 123 studies completing their required Phase 2 drug approval stages." - Anonymous Online Contributor
How many individuals have been admitted to participate in this trial thus far?
"This clinical trial necessitates the recruitment of 150 qualified candidates. Those who meet the inclusion criteria may register at either Indiana University in Indianapolis or University of Minnesota in Minneapolis." - Anonymous Online Contributor
What conditions does Tremelimumab immunotherapy typically treat?
"Tremelimumab immunotherapy is typically prescribed to treat late stage non-small cell lung cancer that cannot be surgically removed. It can also provide relief for advanced ureter urothelial carcinoma, as well as other conditions not mentioned here." - Anonymous Online Contributor
Has Tremelimumab immunotherapy been trialed before?
"The first official investigation of tremelimumab immunotherapy was conducted in 2007 by Research Site. Since then, it has been the subject of 123 completed clinical trials and is presently involved in 340 active studies across Indianapolis, Indiana." - Anonymous Online Contributor
Are there a multitude of locations hosting this research program within the state?
"Currently, the trial is running in 7 locations spanning from Indianapolis to Jacksonville. It may be prudent for potential participants to opt for a location closer to home in order to reduce travel time and expenses." - Anonymous Online Contributor